GLP-1 & Incretin Science

One Compound, Not the Whole Class

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Reported data show a single 5 mg tirzepatide dose reducing peak concentrations of ethinyl estradiol, norgestimate and norelgestromin by 59%, 66% and 55% respectively, with overall exposure down around 20%. Semaglutide, liraglutide and dulaglutide did not show this effect.

Key facts

Compound affected
Tirzepatide
Ethinyl estradiol peak
Reduced ~59%
Norgestimate peak
Reduced ~66%
Norelgestromin peak
Reduced ~55%
Overall exposure
Down ~20%
Not affected
Semaglutide, liraglutide, dulaglutide
Review
Skelley 2024 (PMID 37940101)

Why one compound behaves differently

Tirzepatide engages the GIP receptor as well as GLP-1, and the reported effect on gastric emptying is greater than that of the pure GLP-1 agonists. A larger delay in gastric emptying produces a larger effect on the absorption of anything taken by mouth alongside it, so the interaction tracks the magnitude of the underlying pharmacology.

Why dose escalation compounds it

Delayed gastric emptying attenuates with continued exposure at a stable dose. The effect is largest when a dose is new. A regimen that steps up through several doses therefore reintroduces a strong delay each time it escalates, rather than producing one adaptation that then settles. That is why the reported label position attaches to escalations and not only to starting.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The gap between peak and total, and why it matters here

Peak concentrations fell by 55 to 66% while overall exposure fell by around 20%. That gap is the signature of an absorption-rate effect rather than a loss of drug. For a hormonal contraceptive, though, this is the case where the peak is not merely cosmetic, which is why the finding attracted labelling attention rather than being noted and set aside.

What the label position is

The FDA labelling directs that patients using oral hormonal contraceptives switch to a non-oral method or add a barrier method for four weeks after initiation and for four weeks after each dose escalation. That is a statement of what a regulator has required on a label, reported here as a fact about the label. It is not advice, and decisions of this kind belong with a prescriber.

Why treating this as a class property is the common error

Coverage of GLP-1 drug interactions generally speaks about the class as a unit. Skelley and colleagues examined tirzepatide alongside the GLP-1 receptor agonists in the Journal of the American Pharmacists Association in 2024, and the finding is a contrast rather than a shared property. Applying tirzepatide's interaction profile to semaglutide overstates it; applying semaglutide's to tirzepatide understates it.

The boundary

Tirzepatide and the other compounds named are licensed medicines. Nothing supplied on this site is any of them, is related to them, or interacts with any medicine a person may be taking, because nothing here is for human use in any form.

Quick reference

CompoundEffect on oral contraceptive absorption
TirzepatidePeak reduced 55-66%; exposure down ~20%
SemaglutideNot shown to affect bioavailability
LiraglutideNot shown to affect bioavailability
DulaglutideNot shown to affect bioavailability

Frequently asked questions

Do all GLP-1 drugs affect oral contraceptives?

No. The reported effect is tirzepatide-specific; semaglutide, liraglutide and dulaglutide did not show it.

Why does tirzepatide differ?

It engages the GIP receptor as well as GLP-1 and produces a greater reported delay in gastric emptying, which affects absorption of anything taken by mouth alongside it.

Why does the label mention dose escalation?

The gastric emptying delay is largest when a dose is new and attenuates with continued exposure, so each escalation reintroduces it.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.